Cholinergic dysfunction in parkinson's disease

178Citations
Citations of this article
269Readers
Mendeley users who have this article in their library.
Get full text

Abstract

There is increasing interest in the clinical effects of cholinergic basal forebrain and tegmental pedunculopontine complex (PPN) projection degeneration in Parkinson's disease (PD). Recent evidence supports an expanded role beyond cognitive impairment, including effects on olfaction, mood, REM sleep behavior disorder, and motor functions. Cholinergic denervation is variable in PD without dementia and may contribute to clinical symptom heterogeneity. Early in vivo imaging evidence that impaired cholinergic integrity of the PPN associates with frequent falling in PD is now confirmed by human post-mortem evidence. Brainstem cholinergic lesioning studies in primates confirm the role of the PPN in mobility impairment. Degeneration of basal forebrain cholinergic projections correlates with decreased walking speed. Cumulatively, these findings provide evidence for a new paradigm to explain dopamine-resistant features of mobility impairments in PD. Recognition of the increased clinical role of cholinergic system degeneration may motivate new research to expand indications for cholinergic therapy in PD. © 2013 Springer Science+Business Media New York.

Cite

CITATION STYLE

APA

Müller, M. L. T. M., & Bohnen, N. I. (2013). Cholinergic dysfunction in parkinson’s disease. Current Neurology and Neuroscience Reports, 13(9). https://doi.org/10.1007/s11910-013-0377-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free